Showing results (411-420 of 1,831) with videos related to

Sort By:
Pageof 184
ESMO Open|July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancerI Schlam, D Trapani, S-E Kim, et al.
ESMO Open|July 7, 2026
Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of AmericaL Hart, H S Rugo, P Sharma, et al.
ESMO Open|July 7, 2026
Long-term outcomes, pathological classification and prognostic factors in localised and advanced appendiceal goblet cell adenocarcinoma following cytoreductive surgery, intraperitoneal and systemic chemotherapyM C Strach, O Aziz, D Nonaka, et al.
ESMO Open|July 7, 2026
Molecular effects of ovarian stimulation for fertility preservation in breast cancer: a paired-biopsy analysisY Barral El Gaoui, F Brasó-Maristany, A Borrás Capó, et al.
ESMO Open|July 7, 2026
Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysisR Caputo, G Buono, C Martinelli, et al.
ESMO Open|May 29, 2026
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trialP Filis, X Liu, A Matikas, et al.
ESMO Open|June 5, 2026
Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)H Chen, H Xu, Z Yin, et al.
ESMO Open|May 13, 2026
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumorsU Lassen, E M J van Brummelen, I Melero, et al.
ESMO Open|May 19, 2026
Pembrolizumab combined with nab-paclitaxel and platinum in recurrent/metastatic HNSCC: efficacy, safety, and survival predictive modelL Tang, R Gao, J Yao, et al.
ESMO Open|May 11, 2026
Peripheral blood DNA methylation profile and immune checkpoint inhibitor response in cancer patientsM Kleinberger, V Sunder-Plassmann, A M Starzer, et al.
Pageof 184